GlassScriptPhysician profile
Susan R Wallace
NPI 1740537687
$10,419.45
in general payments reported to CMS, 2019-2025
28 companies · $2,566 in 2025
The $2,566 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,826 · 2022: $1,382 · 2023: $1,483 · 2024: $3,163 · 2025: $2,566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,049 · Travel and Lodging: $1,027 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,048.56 |
| Travel and Lodging | $1,027.47 |
| Education | $135.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,161.44 | 2021-2025 | |
| Axonics, INC. | $1,469.43 | 2024 | Axonics |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $662.42 | 2021-2025 | Xifaxan, Trulance |
| Aimmune Therapeutics, INC. | $618.38 | 2024-2025 | Zenpep |
| Janssen Biotech, INC. | $529.77 | 2021-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $423.56 | 2021-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $379.61 | 2021-2025 | Entyvio, Eohilia |
| Celgene Corporation | $361.83 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $309.55 | 2021-2025 | Epclusa |
| Madrigal Pharmaceuticals | $296.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $251.99 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $181.10 | 2021-2025 | Cimzia, Clenpiq, Rebyota |
| Ardelyx, INC. | $180.74 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $178.62 | 2024-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $174.54 | 2021-2023 | Linzess |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $174.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $167.20 | 2021-2024 | Dificid |
| Genzyme Corporation | $165.16 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $159.47 | 2021-2025 | Ocaliva |
| Lilly USA, LLC | $113.55 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $96.49 | 2025 | Wegovy, Saxenda |
| Pfizer INC. | $88.30 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $84.63 | 2022 | |
| Phathom Pharmaceuticals, INC. | $50.89 | 2023-2024 | Voquezna |
| Celltrion USA INC. | $50.20 | 2025 | Vegzelma |
| Alnylam Pharmaceuticals INC. | $41.78 | 2021-2022 | |
| Evoke Pharma, INC. | $33.94 | 2022-2024 | |
| Braintree Laboratories, INC. | $14.14 | 2025 | Suflave, Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.